ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

9:00AM-10:30AM: Abstract Number: L03

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: 1639

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: 1658

Association Between Anti-Sjögren Syndrome/Scleroderma Autoantigen 1 (SSSCA1) Antibodies and Cancer in Systemic Sclerosis

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:30AM: Abstract Number: 1637

Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:30AM: Abstract Number: 1634

Association of Ultra-processed Food Intake with Risk of Systemic Lupus Erythematosus in Women

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:00AM: Abstract Number: 1629

AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

9:00AM-10:30AM: Abstract Number: 1655

Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus

Abstracts: SLE – Treatment

9:00AM-10:30AM: Abstract Number: L02

Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: 1651

CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus

Abstracts: SLE – Treatment

9:00AM-10:30AM: Abstract Number: 1641

Determination and Characterization of Patient Subgroups with Different Pain Progression in Hand Osteoarthritis

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: 1644

Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Metabolic Syndrome-Associated Osteoarthritis: A Randomized Controlled Trial

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: L05

Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: 1656

Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial

Abstracts: SLE – Treatment

9:00AM-10:30AM: Abstract Number: 1638

Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease in the Veterans Health Administration from 2004 to 2018

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:30AM: Abstract Number: 1645

Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

1
2
3
…
45
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].